Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.
published in: Clinical Cancer Research
date of publication: 2015-03-31
language: English
main subject: chemotherapy, non-small-cell lung carcinoma
Cites articles
There is nothing here
Article - wd:Q35591583